54 results about "Protein domain" patented technology

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.

Provided herein are Avena sativa light, oxygen, voltage 2 (asLOV2) protein domains comprising one or more amino acid substitution(s) as compared to the wild type asLOV2 domain (SEQ ID NO: 1) wherein the mutant asLOV2 domain has an increased magnetic response as compared to the wild type asLOV domain.

A polypeptide linker (2 to 21 amino acids) is connected to a carrier peptide based on the Ioop2 domain of lynx1. The carrier or transporter peptide may be further coupled via the polypeptide linker to a molecule of interest (MOI) or effector agent, such as a protein or protein domain or any other biomolecule (e.g., biomolecules having a molecular weight of 10kDa to 230 kDa). In some embodiments, the complex may be used therapeutically in targeting various neurological disease-causing cellular components.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

The application provides a dengue virus protection and mosquito vector control antigen composition and application thereof. The antigen composition comprises a combination of dengue virus type 1-4 envelope protein domain III polypeptide and Aedes aegypti midgut mucin AaMuc1 antigen polypeptide; the amino acid sequences of the dengue virus type 1-4 envelope protein domain III polypeptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4; and the amino acid sequence of the Aedes aegypti midgut mucin AaMuc1 antigen polypeptide is shown as SEQ ID NO. 5. The prepared vaccine can induce the body to produce neutralizing antibodies against dengue virus type 1-4, achieve the protection of human body from dengue virus infection, induce the production of active antibodies targeting Aedes aegypti midgut mucin 1, inhibit and kill the dengue virus transmission vector Aedes aegypti, and achieve the dual prevention and control of dengue fever from two dimensions of infection prevention and transmission interruption.

The invention relates to a marine-derived bifunctional enzyme as well as a coding gene and application thereof, and belongs to the technical field of biological enzymes. The amino acid sequence of the bifunctional enzyme PpLipO is as shown in SEQ ID NO. 2, and the nucleotide sequence of the bifunctional enzyme PpLipO is as shown in SEQ ID NO. 1. The enzyme comprises an alpha / beta hydrolase structural domain and an osmotic pressure induced protein structural domain, which are respectively PpLipOLip and PpLipOsmC. The novel marine-sourced bifunctional enzyme PpLipO is found for the first time, lipid peroxides are efficiently removed through the synergistic effect of two structural domains, on one hand, the problems that due to the fact that unsaturated fatty acid in fat-containing food is prone to oxidation, the nutritional value of the food is reduced, the sensory quality is degraded, and the edible safety risk is caused can be solved, and on the other hand, the marine-sourced bifunctional enzyme PpLipO can be used for efficiently removing the lipid peroxides; on the other hand, toxic lipid peroxides generated in skin oxidative injury can be cleared away, skin injury is relieved, and the compound can be used for preparing antioxidants.

A multi-domain fusion protein molecule is composed of an antibody single-chain molecule without an immune effect and a polypeptide receptor molecule, which specifically binds to pMHC epitope, or component part thereof or fragment thereof. These protein domains is close to the natural state, can be mixed to form a fusion protein complex molecule having a biological function, and can avoid the risk of immunogenicity caused by introducing artificial flexible peptide chains to link each domain into a single polypeptide chain molecule.

An injectable hydrogel for drug delivery is provided having a first component of repeating protein domains, and a second component cross-linked with the first component. The protein domain in the repeating protein domains is a WW protein sequence interspersed with hydrophilic protein sequences (repeats ranges from 2 to 10). The second component is an inter-bilayer crosslinked multilamellar vesicle. The vesicle is capable of containing drug cargo and eluting the drug cargo. The vesicle is derived from a first lipid and a second lipid. The surface of the vesicle has tethers, which are cross-linked with protein domains of the first component. Control over elution rate of drug cargo is accomplished through stabilization of the vesicles. Gelation occurs in a simple and rapid mixing of the two components without the necessity of additional crosslinking stimuli. Tuning of elution rate is achieved while not losing injectability. Bioresorbable components are used.

The present invention belongs to the field of biomedicine and relates to a method for designing a vaccine with enhanced antigen presentation effect, which is mainly applied to the design and preparation of structural sequences of nucleic acid, protein, and polypeptide vaccines. In the present invention, a target antigen and a ligand, such as a polypeptide or protein domain having the function of binding or recruiting E3 ubiquitin ligase, are both encoded in the same nucleic acid sequence. After the nucleic acid molecule enters the cell, fusion expression of the antigen protein and the E3 ubiquitin ligase ligand is achieved, which promotes degradation of the antigen protein via the proteasome pathway, increases the number and abundance of antigen peptides containing the antigen epitope, forms more peptide-MHC (p-MHC) complexes, and is thus presented on the cell surface, enhancing the subsequent immune response and exerting efficient tumor immunotherapy. The nucleic acid, protein, and polypeptide vaccines provided by the present invention have efficient antigen presentation effect and strong immunogenicity, and have good prospects for clinical application.

The invention provides a preparation method of a genetically modified mouse capable of mediating Tbx1 inherent disorder protein structural domain deletion. The method comprises the following steps: (a) constructing a targeting vector; (b) preparing a gene editing compound; (c) microinjection; (d) embryo transplantation and screening; (e) breeding and establishing a stable strain. Sequencing verifies that the gene modified mouse can stably express the Tbx1 mutant protein which lacks IDR and carries an N-terminal 3xFlag tag, and a homozygote mutant mouse shows remarkable developmental defects such as ventricular septal defect and craniofacial deformity; and an important genetic tool is provided for researching the action mechanism of the phase separation characteristic of the Tbx1 protein in the heart, craniofacial development and congenital heart disease (such as DiGeorge syndrome).

Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.

Provided herein are compositions comprising light-and-magnetoresponsive protein domain, such as engineered light-oxygen-voltage-sensing (LOV) domains, and methods of using the same. The light-and magnetoresponsive proteins domains may be used to form compositions such as fusion proteins comprising heterologous protein components and bioluminescent protein domains with activity that is dependent on the presence of light, e.g., light emitted by a reaction catalyzed by the bioluminescent protein domain, and on the presence of a magnetic field.

Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.

A CRISPR-Cas system and applications thereof are provided, also related to a Cas protein, a fusion protein and a guide polynucleotide. The Cas protein has at least 50% sequence identity compared to the sequence set forth in any one of SEQ ID NOs: 1-184, 426-428. The fusion protein comprises the Cas protein fused to a protein domain and / or a polypeptide tag. The guide polynucleotide comprises a direct repeat sequence having at least 70% sequence identity to any one of SEQ ID NOs: 185-199, 245-247, 287-303, 369 and 370-373, and a guide sequence engineered to hybridize to a target nucleic acid. The CRISPR-Cas system comprises a Cas protein having at least 90% sequence identity compared to the sequence set forth in any one of SEQ ID NOs: 1-184, 426-428, or a nucleic acid encoding thereof, and a guide polynucleotide or a nucleic acid encoding thereof.

A thermally responsive nanosphere for binding to biofilms including a gold nanoparticle core functionalized with a polyethylene glycol; an R2ab fusion protein construct including an anchor that is a stable globular domain having a surface accessible cysteine residue, a linker, an S. epidermidis R2ab protein of SEQ ID NO. 1, and an elastin-like polypeptide. The linker may be a protein having SEQ ID NO. 7; and the anchor may be a modified third IgG binding domain from streptococcal protein G (GB3) having SEQ ID NO. 3, a ubiquitin protein having SEQ ID NO. 4, a Pin1 WW domain having SEQ ID NO. 5, and a fibronectin protein domain 3FN3 having SEQ ID NO. 6. A method for treating a biofilm containing S. epidermidis bacteria by binding a plurality of the nanospheres to the biofilm and exposing the biofilm to laser irradiation.

The present disclosure provides compositions and methods for the selective transduction and genome editing of human cells (e.g., hematopoietic stem and progenitors cells, HSPCs) using engineered viral like particles (eVLPs). Aspects of the disclosure provide eVLP compositions comprising fusion proteins comprising a targeting moiety. In some embodiments, the fusion proteins comprise a cytokine conjugated to a transmembrane protein and / or an envelope glycoprotein. In other embodiments, the fusion proteins comprise a targeting moiety domain, a stalk protein domain, a transmembrane and / or envelope glycoprotein domain. Targeted-eVLP architectures comprising various targeting domains, stalk domains, transmembrane domains, and envelope glycoproteins are also provided herein. Other aspects of the disclosure provide eVLP compositions comprising envelope glycoproteins comprising non-natural sugars and methods of conjugating said eVLPs to various targeting moieties using bio-orthogonal click chemistry. Polynucleotides, vectors, cells, and kits useful for producing the articles, and performing the methods, described herein are also provided.

To provide compositions and methods for increasing efficiency of targeted genome / epigenetic modification in eukaryotic cells.SOLUTION: A fusion protein comprises at least one nucleosome interacting protein domain linked to a programmable DNA modification protein. A method for increasing efficiency of targeted genome or epigenetic modification in an eukaryotic cell comprises introducing, into the eukaryotic cell, the fusion protein or a nucleic acid encoding the fusion protein.SELECTED DRAWING: None

Provided are a method, an apparatus, and a computer program for predicting interaction between a compound and a protein. A method for predicting interaction between a compound and a protein according to some embodiments of the present disclosure may comprises the steps of: acquiring learning data composed of compound data for learning, protein data for learning, and interaction scores; constructing a deep-learning model by using the acquired learning data; and predicting interaction of a given compound and protein through the constructed deep-learning model. Through the learning of the deep-learning mode with the exclusion of amino acid sequences associated with protein domains having a negative influence on interactions from amino acid sequences of proteins for learning, the interaction between a given compound and protein in the in vivo environment can be accurately predicted.

The present invention discloses a drug for treating inflammatory bowel disease, wherein the drug is an extracellular vesicle loaded with a targeted drug and a Trim21 protein domain, wherein the targeted drug is capable of targeting the extracellular vesicle to CD4 + The targeted drug for T cells, wherein the Trim21 protein domain is a Trim21 protein domain lacking ubiquitination function. + The T cell targeted drug and the Trim21 protein domain lacking ubiquitination function are loaded into extracellular vesicles, and the targeted drug transports the entire drug-loaded extracellular vesicle to CD4 + T cells then compete with the intracellular host Trim21 for binding to FBXW7 through the Trim21 protein domain that lacks ubiquitination function, thereby antagonizing the effect of intestinal flora in promoting Th17 cell differentiation, thereby achieving the purpose of treating inflammatory bowel disease.

The invention discloses a preparation method and application of an oral recombinant fusion fish growth hormone and a PEGylated fish growth hormone, and relates to the fields of gene recombination technology and pharmaceuticals. The amino acid sequence of the fusion fish growth hormone in the invention comprises a transduction protein domain sequence, a linker protein sequence and a universal fish growth hormone amino acid sequence. The invention adopts a Piscinenodavirus (PNV) transduction domain sequence, a Grass Carp Reovirus (GCRV) transduction domain sequence, and a Protein Kinase Activated Receptor 2 (Par2) TMhelix1 as a cell-penetrating peptide to guide the growth hormone into cells, thereby improving the protein transduction rate. Meanwhile, mPEG-NH2 is used to PEGylate the fusion protein, thereby improving the half-life of the fusion protein and making it suitable for use in juvenile fish.

The invention discloses a protein structural domain function prediction method and device based on a long short-term memory network, terminal equipment and a storage medium, and the method comprises the steps: obtaining a to-be-detected protein amino acid sequence, and coding the to-be-detected protein amino acid sequence to obtain a coded sequence; the coded sequence is input into a bidirectional long short-term memory network, the bidirectional long short-term memory network extracts a forward hidden state from the N end to the C end of the coded sequence through a forward LSTM, extracts a reverse hidden state from the C end to the N end of the coded sequence through the forward LSTM, and the forward hidden state and the reverse hidden state are spliced to obtain a bidirectional hidden state; performing global pooling operation on the bidirectional hidden states of all the time steps to generate a global feature vector; and carrying out linear transformation on the global feature vector, and predicting to obtain the protein structural domain function of the amino acid sequence of the to-be-detected protein. By implementing the method, the efficiency of protein structure domain function analysis can be improved.

The present invention relates to the field of pharmaceutical knowledge graph technology, specifically a method and system for constructing a pharmaceutical knowledge graph based on artificial intelligence, comprising the following steps: collecting the molecular structure of a drug and its corresponding target protein sequence through database query, numerically encoding the molecular structure data of the drug, extracting molecular fingerprints and protein domain features, and combining the drug's chemical properties with protein sequence characteristics to form a drug and protein feature set. In the present invention, through precise analysis of the drug's molecular structure and its target protein sequence, the innovative solution significantly enhances the understanding of the interaction between drugs and proteins, allowing researchers to directly extract key features from the data and monitor the dynamic changes in drug effects. This not only accelerates the drug development process and optimizes treatment plans, but also provides strong data support for personalized medicine by dynamically tracking the interaction between drug side effects and pathological characteristics.

The present invention relates to the field of genetic engineering. In particular, the present invention relates to a genome editing fusion protein comprising a CRISPR effector protein domain and a deaminase domain, as well as a bifunctional genome editing system comprising said genome editing fusion protein and uses thereof.

The application discloses a novel coronavirus vaccine for promoting specific IgA antibody secretion and a construction method and application thereof, belongs to the field of immunology and the field of genetic engineering, and is an immunogen developed by taking S protein as the vaccine (the same is true for other structural proteins of the novel coronavirus, such as N protein or E protein or M protein), aims to improve the mucosal IgA expression level after immunization of the vaccine, and constructs a novel coronavirus vaccine which can significantly promote human B lymphocytes to secrete specific anti-S protein IgA antibodies in the process of stimulating the immune response of the body by the S protein, and further enhance the mucosal protection and defense function, and provides a construction technology, method and application thereof. By introducing a specific protein domain, IL-5 (referred to as 'adjuvant protein'), into the S protein of the novel coronavirus, a novel coronavirus vaccine modified by the 'adjuvant protein' is formed.

The application provides a coordination nanometer assembly of a chiral cyclic peptide and a manganese ion, a preparation method and application thereof, the method of the application combines a manganese superoxide dismutase protein domain with a unique tumor microenvironment of a melanoma high tyrosinase, and first designs polypeptide sequences with different chirality L‑ Y D‑ h L‑ D D‑ h、 L‑ Y L‑ H L‑ D L‑ H and D‑ y D‑ h D‑ d D‑ h, regulates polypeptide chirality, improves in-vivo circulation stability and cell entry efficiency of the nanometer assembly, coordinates self-assembly of manganese and the chiral cyclic peptide, simulates in-situ oxidation of the tumor microenvironment for photothermal therapy, and coats cell membranes. The method of the application is simple, the experimental conditions are mild, and the method is easy to operate, the cell membrane coated nanometer assembly prepared by the method not only has long circulation stability and high cell entry efficiency, but also can realize mild photothermal therapy through in-situ oxidation, release manganese ions to activate the CGAS-STING pathway for tumor immunotherapy, and has potential application value in the field of tumor combination therapy.

The present invention relates to chemically inducible split protein actuators (CISPA), which utilize ligand-binding proteins or protein domains originating from humans or other organisms, which are rationally split into two fragments that reassemble only in the presence of a cognate ligand. In particular, the invention relates to their design, manufacture, structure, and uses. The designed CISPAs can be used to regulate cellular processes such as gene expression, conditionally reconstitute of the function of a protein such as enzyme activity, as biological sensors, or for other applications.

Disclosed are vaccine compositions, in particular, polyvalent icosahedral compositions for presentation of an HA1 influenza antigen. The disclosed compositions may contain an S particle comprising a norovirus (NoV) S domain and an HA1 influenza antigen, which may be linked via a linker protein domain operatively connected to the norovirus S domain and an influenza antigen. Fusion proteins for producing the vaccine compositions, and methods of using the disclosed vaccine composition are also provided.

The invention discloses a vaccine for preventing and treating swine Japanese encephalitis virus and application, and belongs to the field of biological pharmacy for livestock. The CHO stable expression cell line expressing the E protein Domain III is constructed, transcription and protein expression levels are remarkably improved, the cell line grows under the glutamine-free condition, accumulation of metabolites such as ammonia is reduced, and cell activity and long-term culture stability are improved. The FC fusion protein is added after the ED3 gene sequence through the flexible Linker, so that the affinity chromatography purification process is simplified, the recovery rate and the purity are improved, and the production cost is reduced; meanwhile, the high-efficiency expression of CHO cells is combined, so that the purified protein yield is higher than 2g / L, which is far better than that of a traditional method, and the large-scale requirement of veterinary vaccines is met. The vaccine provided by the invention has no pathogen residual risk, the safety is higher than that of the traditional inactivated or attenuated live vaccine, and the vaccine which is safe, reliable and good in immunogenicity is provided for preventing and treating infection of the swine Japanese encephalitis virus.

Some aspects of this disclosure provide compositions, strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins capable of inducing a cytosine (C) to guanine (G) change in a nucleic acid (e.g., genomic DNA) are provided. In some embodiments, fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9) and nucleic acid editing proteins or protein domains, e.g., deaminase domains, polymerase domains, and / or base excision enzymes are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9), and nucleic acid editing proteins or domains, are provided.